TMCnet News
BlueSphere Bio to Present at the 7th Annual CAR-TCR SummitPITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the company will present a poster, at the 7th Annual CAR-TCR Summit, being held in Boston, MA from September 19 – 22, 2022. The summit brings together over 200 industry leaders to discuss discovery through to the commercialization of viable cell therapies. Title: TCXpress™ and iTCXpress™: A Direct, High-throughput Platform Utilizing Parallel Processes for Efficient and Cost-Effective Discovery and Characterization of Novel TCRs. Presenters: Jennifer Roy, Associate Scientist, BlueSphere Bio and Stephanie Stras, Associate Scientist, BlueSphere Bio Date: September 22, 2022 Time: 1:00-2:00pmET About TCXpress™/p>
About BlueSphere Bio BlueSphere Bio is the first translational sciences stand-alone company formed by UPMC Enterprises, the innovation, commercialization, and venture capital arm of the Pittsburgh-based health system. The company was founded upon the unique, advanced TCR discovery platform - TCXpress™, designed to isolate and functionally characterize TCRs with speed and efficiency. BlueSphere anticipates filing its first IND application in the first quarter of 2023 for a novel TCR T-cell therapy for patients with high-risk leukemias, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in the context of allogeneic stem cell transplantation. Concurrent with its program for hematologic cancers, BlueSphere is deploying TCXpress™ and NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to target patient-specific neoantigens and anticipates additional virtual patient data from multiple solid tumor types over the next several months. Company Contact Media Contact
|